Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
Immune-checkpoint blockade (ICB) has demonstrated efficacy in many tumor types, but predictors of responsiveness to anti-PD1 ICB are incompletely characterized. In this study, we analyzed a clinically annotated cohort of patients with melanoma (n = 144) treated with anti-PD1 ICB, with whole-exome an...
Main Authors: | Liu, David V. (Author), Liu, Derek (Author), Jerby-Arnon, Livnat (Author), Vokes, Natalie I. (Author), Margolis, Claire A. (Author), Conway, Jake (Author), He, Meng Xiao (Author), Elmarakeby, Haitham (Author), Dietlein, Felix (Author), Miao, Diana (Author), Tracy, Adam (Author), Izar, Benjamin (Author), Regev, Aviv (Author), Van Allen, Eliezer M. (Author) |
---|---|
Other Authors: | Broad Institute of MIT and Harvard (Contributor) |
Format: | Article |
Language: | English |
Published: |
Springer Science and Business Media LLC,
2020-06-17T18:36:59Z.
|
Subjects: | |
Online Access: | Get fulltext |
Similar Items
-
Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1−CD8+ Tumor-Infiltrating T Cells
by: Regev, Aviv
Published: (2020) -
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
by: Bin Zhao, et al.
Published: (2020-07-01) -
Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair-Deficient Colorectal Cancer
by: Liu, David, et al.
Published: (2020) -
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
by: Jake R. Conway, et al.
Published: (2018-11-01) -
RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer
by: Elizabeth Ahern, et al.
Published: (2018-06-01)